A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment

KEI FUJIO1, MASAMI WATANABE1,2, HIDEO UEKI1, SHUN-AI LI1,2, RIE KINOSHITA3, KAZUHIKO OCHIAI4, JUNICHIRO FUTAMI3, TOYOHIKO WATANABE1, YASUTOMO NASU1,2 and HIROMI KUMON1

1Department of Urology, Okayama University; 2Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama University; 3Department of Biotechnology, Graduate School of Natural Science and Technology, Okayama University, Okayama; 4Department of Veterinary Nursing and Technology, School of Veterinary Science, Nippon Veterinary and Life Science University, Musashino-shi, Tokyo, Japan

Received September 9, 2014; Accepted December 3, 2014

DOI: 10.3892/or.2015.3770

Abstract. Immunotherapy is one of the attractive treatment strategies for advanced prostate cancer. The US Food and Drug Administration (FDA) previously approved the therapeutic vaccine, sipuleucel-T, which is composed of autologous antigen-presenting cells cultured with a fusion protein [prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-stimulating factor (GMCSF)]. Although sipuleucel-T has been shown to prolong the median survival of patients for 4.1 months, more robust therapeutic effects may be expected by modifying the vaccination protocol. In the present study, we aimed to develop and validate a novel vaccination strategy using multiple PAP-fused cytokines for prostate cancer treatment. Using a super gene expression (SGE) system that we previously established to amplify the production of a recombinant protein, significant amounts of PAP-fused cytokines [human GMCSF, interleukin-2 (IL2), IL4, IL7 and mouse GMCSF and IL4] were obtained. We examined the activity of the fusion proteins in vitro to validate their cytokine functions. A significant upregulation of dendritic cell differentiation from monocytes was achieved by PAP-GMCSF when used with the other PAP-fused cytokines. The PAP-fused human IL2 significantly increased the proliferation of lymphocytes, as determined by flow cytometry. We also investigated the in vivo therapeutic effects of multiple PAP-fused cytokines in a mouse prostate cancer model bearing prostate-specific antigen (PSA)- and PAP-expressing tumors. The simultaneous intraperitoneal administration of PAP-GMCSF, -IL2, -IL4 and -IL7 significantly prevented tumor induction and inhibited the tumor growth in the PAP-expressing tumors, yet not in the PSA-expressing tumors. The in vivo therapeutic effects with the multiple PAP-fused cytokines were superior to the effects of PAP-GMCSF alone. We thus demonstrated the advantages of the combined use of multiple PAP-fused cytokines including PAP-GMCSF, and propose a promising prostatic antigen-vaccination strategy to enhance the therapeutic effects.

Introduction

Prostate cancer is a commonly diagnosed malignant disease in males worldwide, and there are no effective treatment options once the cancer becomes metastatic and refractory to hormonal therapy and chemotherapy. In prostatic tissues, including both the normal prostate and prostate cancer, the expression of several specific proteins, such as prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), prostatic acid phosphatase (PAP) and prostate secretory protein-94 (PSP94) has been described (1-3). By targeting these prostate-specific proteins to establish anti-tumor vaccines, immunotherapy has been developed, and has recently been suggested to have potential for the treatment of prostate cancer (4-7).

PAP is a secretory prostate-specific protein that consists of 354 amino acids with an estimated molecular mass of 41 kDa (1,2). Homologs of the human PAP gene have been identified in rats and mice, and these proteins respectively share 75 and 81% homology with the human protein at the amino acid level (2). PAP is overexpressed in 95% of prostate cancer tissues (8), and the tissue specificity of PAP makes it an attractive target antigen for immunotherapy against prostatic malignancy (8,9). Several vaccine candidates have been developed based on the PAP protein using cell-based medicine (10,11), DNA vaccines (12) or peptide antigens (13,14).

Using the full-length PAP protein as a vaccine target, sipuleucel-T (Provenge®, Dendreon Inc., Seattle, WA, USA), an autologous active cellular immunotherapy, was developed for the treatment of metastatic castration-resistant prostate cancer (10). The cellular agent is manufactured from individual peripheral monocytes enriched by leukapheresis, and is an antigen-presenting cell vaccine loaded ex vivo with a fusion protein linking PAP to granulocyte-macrophage colony-stimulating factor.
colony-stimulating factor (GMCSF) (15,16). After incubation with the PAP-GMCSF fusion protein, the immunologically activated cells are intravenously administered to patients every two weeks for a total of three infusions. A placebo-controlled randomized phase III trial demonstrated that the personalized cell-based vaccine showed evidence of efficacy in reducing the risk of death among patients with prostate cancer refractory to hormonal therapy (10). In the patients treated with sipuleucel-T, there was a relative reduction of 22% in the risk of death compared with the placebo group, representing a 4.1-month improvement in median survival (25.8 months in the sipuleucel-T group vs. 21.7 months in the placebo group). Based on the results of a phase III study, the US Food and Drug Administration (FDA) approved sipuleucel-T for the treatment of prostate cancer in April 2010, and this was the first antigen-specific immunotherapy officially approved in a developed country.

Although sipuleucel-T can prolong the overall survival in patients with progressive prostate cancer, more robust immunological effects seem to be possible that can further improve survival. In order to enhance the therapeutic effects of the PAP-GMCSF fusion protein, we experimentally tried to modify the methods and to develop a novel vaccination strategy with the additional use of multiple PAP-fused cytokines, including human interleukin-2 (IL2), IL4, and IL7. The reason for adding these interleukins is that these cytokines can potently activate antitumoral immune cells and upregulate the effects of the therapeutic vaccination for cancer treatment (17-19).

The cost for sipuleucel-T is reported to be 93,000 US$ per course of treatment, thus making this therapeutic vaccine an expensive treatment option (11). One of the ways to reduce the pharmacological cost is to increase the production efficiency of the PAP-GMCSF fusion protein. Since we previously established a super gene expression (SGE) cassette to amplify the production of a recombinant protein in 293-F cells (20,21), we herein attempted to apply this mammalian expression system to produce multiple PAP-fused cytokines. In the present study, we validated the activity of the PAP-fused proteins as cytokines and demonstrated the advantages of the combined use of multiple PAP-fused cytokines in in vitro and in vivo situations.

Materials and methods

Construction of the SGE plasmid vectors encoding PAP-fused cytokines. The construction of a plasmid vector with the SGE system was performed as previously described (20,21). The gene expression cassette with the CMV promoter, sequences of RUS5', bovine growth hormone polyadenine nucleotides (BGH polyA) and tandem elements of triple translational enhancers hTERT, SV40 and CMV was artificially synthesized and cloned into the pIDT-SMART vector (Integrated DNA Technologies, Inc., Coralville, IA, USA) (Fig. 1A). The RUS5' sequence [269 bp, accession no. J02029 (374-642)] was derived from the R segment and part of the U5 sequence of the HTLV type 1 long terminal repeat and was used to enhance the stability of DNA and RNA and increase the translation efficiency (21). The tandem element of the triple translational enhancers consists of the hTERT enhancer [189 bp, accession no. Q264729 (1618-1806)], SV40 enhancer [319 bp, accession no. AY864928 (2156-2474)] and CMV enhancer [479 bp, accession no. AJ318513 (159-637)]. The tandem sequence of the hTERT, SV40 and CMV enhancers is the main element of the SGE system. The SGE plasmid encoding a fusion protein of full-length human PAP and one of the cytokines (human GMCSF, IL2, IL4, IL7 or mouse GMCSF or IL4) were then constructed and used to express the recombinant PAP-fused cytokines. The fusion cytokines were designed to be histidine-tagged for purification.

Preparation of the recombinant PAP-fused cytokines. The recombinant PAP-fused cytokines were expressed by the FreeStyle 293 expression system (Invitrogen, Carlsbad, CA, USA) with the respective SGE plasmids according to the manufacturer's instructions. The expression system was designed to allow the transfection of suspended 293-F cells (derived from HEK293 cells) in serum-free culture medium. Transient transfection with the plasmid vector was performed, and the secreted recombinant fusion protein in the culture supernatant was collected. The PAP-fused cytokines were purified using the histidine tag included in the fusion protein, as previously described (22). The recombinant PAP-fused cytokines were stocked and maintained at -80°C until use. The PAP-fused human and mouse cytokines were analyzed for the protein amount, purity and concentration by examining the densitometry of the bands on SDS-PAGE with Coomassie brilliant blue (CBB) staining.

Preparation and culture conditions of blood mononuclear cells. Human peripheral blood mononuclear cells (PBMCs) were prepared from the blood of healthy donors by the standard procedure using Ficoll-Paque centrifugation (22). This research was carried out on humans following the international and national regulations. Written informed consent was obtained from the subjects. For some experiments, human CD14-positive monocytes were purchased from Lonza (Walkersville, MD, USA). Mouse blood was obtained from the inferior vena cava, and the mononuclear cells were prepared by Ficoll-Paque centrifugation. The blood mononuclear cells and CD14-positive monocytes were cultured either in LGM-3 medium (Lonza) alone or in the presence of recombinant PAP-fused cytokines under the indicated conditions. As a positive control for the differentiation of human dendritic cells, the PBMCs and CD14-positive monocytes were cultured in LGM-3 medium supplemented with human granulocyte-macrophage colony-stimulating factor (hGMCSF; 2 ng/ml) and human interleukin-4 (hIL4; 2 ng/ml) (both from R&D Systems, Minneapolis, MN, USA) (17,22). The cells were cultured at 37°C in humidified incubators containing air with 5% CO2.

Proliferation assay using TF-1 cells. TF-1, a human GMCSF-dependent proliferative cell line (23,24), was used to analyze the cytokine activity of PAP-hGMCSF. TF-1 cells (10^5 cells/well) were plated on 96-well plates and cultured as previously reported (23). The PAP-hGMCSF was added to the culture medium at the indicated concentrations derived from a 3-fold serial dilution. hGMCSF was used as a positive control for the GMCSF-dependent proliferation. After three days of incubation, the proliferation of the TF-1 cells was analyzed with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, according to the manufacturer's instructions.
Flow cytometric analysis. To analyze the proliferation of CD8⁺, CD4⁺ and CD19⁺ lymphocytes, flow cytometry was performed as previously described (22). Human PBMCs (75x10⁴ cells/well) were incubated with PAP-hIL2 (1 µg/ml) for four days on 6-well plates, and then the floating cells were examined for each surface antigen. The cells were stained with the following FITC-conjugated antibodies for 60 min on ice: CD8 (551347; BD Pharmingen, San Diego, CA, USA) as a marker for cytotoxic T lymphocytes, CD4 (555346) for helper T lymphocytes and CD19 (555412) for B lymphocytes. After staining, 2x10⁴ cells were acquired on a FACSCalibur flow cytometer and analyzed using the CellQuest software program (both from Becton-Dickinson, Franklin Lakes, NJ, USA).

Animal experiments. The RM9 mouse prostate cancer cell line was kindly provided by Dr T.C. Thompson (The University of Texas, Houston, TX, USA) (25) and was used in the animal experiments. In our experimental set-up, we prepared PSA-RM9 and PAP-RM9 cells stably expressing the human PSA or PAP protein, respectively. The stable clones of RM9 cells were established by the transfection of plasmids encoding the full-length human PSA or PAP genes and a neomycin-resistance gene, as previously described (20,21,26). Using the PSA-RM9 and PAP-RM9 cells, we developed a mouse prostate cancer model bearing both PSA- and PAP-expressing tumors. The in vivo experimental schedule and treatments with the PAP-fused cytokines are shown in Fig. 4A. Since IL2 and IL7 possess cross-reactivity between human and mouse species (27-29), we used PAP-human IL2 and PAP-human IL7 instead of PAP-mouse IL2 and PAP-mouse IL7, respectively. A total of nine intraperitoneal administrations of the PAP-fused cytokines were performed. On day 7, the PSA-RM9 and PAP-RM9 cells were subcutaneously inoculated into the left and right femurs, respectively, of C57BL/6 adult male mice. All mice were examined for the tumor formation and for the tumor size on day 21, and then were sacrificed. Animal experiments using anticancer cytokines were approved by the Animal Care and Use Committee, Okayama University.

Statistical analysis. The data are expressed as the means ± standard error. Student’s t-test or the Chi-square test was used to determine the statistical significance of differences between the two groups. Differences were considered to be statistically significant for values of p<0.05.

Results

Production of recombinant multiple PAP-fused cytokines using the SGE system. We previously developed the SGE system in order to improve the protein production by conventional gene expression systems (20,21). In the gene expression cassette with the SGE system, triple translational enhancer sequences of hTERT, SV40 and the CMV enhancer were inserted downstream of the BGH polyA sequence (Fig. 1A). We recently reported that the SGE system significantly enhanced adenoviral vector-mediated gene expression (~2- to 5-fold) in human cancer cell lines, as determined by western blot analysis) in comparison to the system using conventional gene expression (20). Therefore, we herein attempted to apply this mammalian expression system to produce the multiple PAP-fused cytokines.

The amount of protein produced and the purity of the recombinant PAP-fused cytokines produced by the SGE system
were analyzed by SDS-PAGE with CBB staining (Fig. 1B). As a result, a significant amount of PAP-fused cytokines was obtained in the serum-free culture medium of the 293-F cells on day 5 by the transient gene expression. The recombinant fusion proteins were recognized as single bands by gel electrophoresis. The concentration (mg/l) of the fusion proteins in the medium was calculated: PAP-hGMCSF, 123.3; PAP-hIL2, 91.7; PAP-hIL4, 96.9; PAP-hIL7, 64.5; PAP-mGMCSF, 94.2; PAP-mIL4, 62.8.

Recombinant PAP-fused cytokines maintain their cytokine activity. In order to confirm the cytokine activity of the recombinant PAP-fused cytokines, we conducted in vitro experiments with PAP-hGMCSF and PAP-hIL2. It is known that human GMCSF stimulates the proliferation of TF-1 cells (23,24). Therefore, we first analyzed the growth dependency of TF-1 cells by adding PAP-hGMCSF in the culture medium. The cell proliferation at the indicated concentrations was assayed by determining the absorbance at 570 nm in the MTT assay. (B) Proliferation of CD8⁺, CD4⁺ and CD19⁺ lymphocytes following treatment with PAP-hIL2 was analyzed by flow cytometry. Human peripheral blood mononuclear cells (PBMCs) were incubated with PAP-hIL2 (1 µg/ml) for four days, and then the floating cells were examined for each surface antigen. GMCSF, granulocyte-macrophage colony-stimulating factor.

To confirm the ability of the multiple PAP-fused cytokines to induce the differentiation of monocytes into dendritic cells, purified monocytes from PBMCs were cultured in the presence of recombinant fusion cytokines. Since GMCSF has been considered to be an essential cytokine for the differentiation and maturation of dendritic cells (17), we basically used PAP-GMCSF and attempted to combine the other PAP-fused cytokines with it in order to augment the immunological effects. During the first two days of treatment with the multiple PAP-fused cytokines (including PAP-hGMCSF), most of the monocytes displayed cellular elongation (Fig. 3A). The ratio of elongated monocytes in samples treated with the multiple fusion cytokines was higher than that in the cells treated with PAP-hGMCSF alone. With regard to the monocytes cultivated with medium alone, there were only a few cells with dendritic–cell like features.

We next quantified the dendritic cell differentiation induced by the treatment with multiple PAP-fused cytokines, including PAP-GMCSF. Since it has been well established that dendritic cells can be differentiated by incubation with GMCSF and IL-4 (17,22), we referred to the morphological features of cells treated with these cytokines as a positive control for dendritic cells (Fig. 3B). After the incubation with PAP-fused human cytokines, the number of cells developing into human dendritic cells was counted in several microscopic fields. When treated with the multiple fused cytokines, the number of developing dendritic cells was significantly increased in comparison to those treated with PAP-GMCSF alone (Fig. 3C). The enhanced differentiation of mouse dendritic cells was also confirmed by cultivating the blood mononuclear cells with multiple fusion cytokines, including PAP-mGMCSF and PAP-mIL4 (Fig. 3D). These results indicated that the differentiation of dendritic cells was enhanced by the combined use of multiple PAP-fused cytokines, including PAP-GMCSF.

In vivo therapeutic effects are enhanced by the combined use of multiple PAP-fused cytokines, including PAP-GMCSF. The in vitro results in the present study indicated the possibility that a PAP-fused cytokine-based in vivo increase in immune cells may upregulate the antitumor immune response by targeting the PAP molecule. In order to investigate the antitumor effects of PAP-fused cytokines, in vivo experiments were performed using a mouse prostate cancer model bearing both PSA- and PAP-expressing tumors (Fig. 4A). As a PAP-targeting vaccine, the multiple PAP-fused cytokine treatment would be expected to be most effective for use against the initial stages of prostate cancer or for minimal disease. Therefore, the vaccine was started to be administered before the cancer cell inoculation in our preclinical mouse model.

In the preliminary experiments, in vitro and in vivo stable expression of the PSA and PAP proteins was confirmed for the PSA-RM9 and PAP-RM9 cells, respectively (data not shown). Since IL2 and IL7 possess cross-reactivity between humans and mice (27-29), we used PAP-human IL2 and PAP-human IL7 instead of PAP-mouse IL2 and PAP-mouse IL7, respectively. We first analyzed whether the PAP-fused cytokines could protect mice against challenge with a PAP-expressing tumor. The incidence of PSA-RM9 and PAP-RM9 tumor formation was analyzed on day 21 after the subcutaneous inoculation of cancer cells. In the present study, PSA-expressing
tumors derived from PSA-RM9 cells were monitored for the effects of the PAP-based immunological treatments. The co-administration of PAP-GMCSF, -IL2, -IL4 and -IL7 significantly prevented the tumor induction of PAP-RM9 cancer cells (Fig. 4B). On the other hand, the treatment with PAP-GMCSF alone failed to prevent the tumor formation.

We next investigated whether PAP-fused cytokines inhibits PAP-RM9 tumor growth in vivo. Significant inhibition of the tumor growth was observed in the groups treated with both PAP-GMCSF alone and with the co-administration of PAP-GMCSF, -IL2, -IL4 and -IL7 (Fig. 4C). The in vivo therapeutic effects of the multiple PAP-fused cytokines were superior to the effects observed with PAP-GMCSF treatment alone. For the control PSA-expressing tumors derived from PSA-RM9 cells, no significant therapeutic effect was observed following the treatments with PAP-fused cytokines. Based on the results of the tumor challenge and growth, it was concluded that PAP-specific immune activation occurred in the mice treated with the PAP-fused cytokines, and the antitumor effects were significantly enhanced by the additional cytokine (IL2, IL4 and IL7) fusion proteins.

**Discussion**

In the present study, we experimentally validated a PAP-GMCSF-based vaccine strategy with multiple PAP-fused cytokines for the immunotherapy of prostate cancer. We also demonstrated the availability of the SGE system for the production of recombinant PAP-fused cytokines. With regard to the SGE system, we originally developed it as a gene expression system that allows the gene of interest to be expressed with very high efficiency in 293-F cells (20,21). In this SGE construct of the vectors, the linkage of triple translational enhancer sequences of hTERT, SV40 and CMV enhancers was inserted into a site downstream of the sequence of the BGH polyA. The CMV promoter driving SGE system robustly enhanced the gene expression of plasmid and adenoviral vectors in comparison to the cassette with CMV promoter alone (20). The superiority of the CMV promoter-SGE system was also observed compared to the gene expression cassette with EF-1α and CAG promoters alone (21). Using this SGE system, we succeeded in producing a significant amount of the PAP-fused cytokines (human GMCSF, IL2, IL4, IL7, and mouse GMCSF and IL4) in the medium of 293-F cells. The recombinant proteins were easily concentrated for use in the experiments and demonstrated activity as cytokines.

We herein examined the activity of the fusion proteins as cytokines in vitro, and significant upregulation of dendritic cell differentiation from monocytes was achieved by treatment with PAP-GMCSF when it was used with the other PAP-fused cytokines. The PAP-fused human IL2 led to significantly increased proliferation of T and B lymphocytes,
as determined by flow cytometry. We thus validated the cytokine functions of the PAP-fused cytokines. Dendritic cells are antigen-presenting cells that play important roles in anticancer immune responses. GMCSF has been considered to be the main cytokine required for the differentiation and maturation of dendritic cells (17). The combined use of GMCSF and IL4 is the most extensively characterized and utilized combination for the in vitro differentiation of dendritic cells from peripheral blood monocytes (17,22). In terms of the effects of the different cytokine combinations with GMCSF on the development of dendritic cells, the addition of IL2 and IL7 also plays important roles (17,30-32). Moreover, previous reports indicate that IL2 induces the differentiation and/or maturation toward a dendritic cell phenotype without GMCSF (31), and could enhance the motility of dendritic cells (30).

With regard to the other immune cells (other than antigen-presenting cells), CD4+ and CD8+ T lymphocytes, CD19+ B lymphocytes and natural killer (NK) cells all play important roles in antitumor immunity. Interleukins, including IL2, IL4 and IL7, are known to exhibit and enhance antitumor effects, not only through the activation of these antitumor immune cells, yet also via the activation of macrophages and lymphokine-activated killer (LAK) cells (3,33-35). Thus, as a result of the enhanced cancer-specific immunity following the simultaneous activation of these immune cells, the combined use of multiple cytokines is a promising strategy (Fig. 5). Our results also indicate that this strategy could be adaptable for
that PAP (114-128) is a highly relevant peptide on which to molecules (36).

To further demonstrate the utility of the multiple PAP-fused cytokines, we investigated the in vivo therapeutic effects of the recombinant proteins in a mouse prostate cancer model bearing both PSA- and PAP-expressing tumors. The co-administration of PAP-GMCSF, -IL2, -IL4 and -IL7 significantly prevented tumor induction and inhibited tumor growth in the PAP-expressing tumors, yet not in the PSA-expressing tumors. The finding indicates that PAP-specific immune activation occurred in the mice treated with the PAP-fused cytokines. We also demonstrated that the tumor growth suppression by the multiple PAP-fused cytokines was superior to the effect with PAP-GMCSF alone. Therefore, the vaccination against PAP was significantly upregulated by the additional cytokine (IL2, IL4 and IL7) fusion proteins. The in vivo results are consistent with our in vitro findings showing the increased induction of dendritic cells and lymphocytes by the fusion cytokines. It is conceivable that the PAP-fused cytokines, including PAP-GMCSF, induced the robust differentiation of the monocytes into antigen-presenting dendritic cells, resulting in the activation of PAP-specific CD4+ and CD8+ T lymphocytes in the treated mice. These activated T lymphocytes are then thought to work against the PAP-expressing tumor lesions in the mouse model, targeting the antigen and mediates the antitumor responses. On the other hand, based on the increased induction of CD19+ B lymphocytes by the fusion cytokines in vitro, the antitumor effects could also be partially due to the humoral immunity of the PAP-specific antibodies induced in the mouse model.

A question that remains to be answered is associated with the peptide epitopes of the PAP antigen in the cellular arm of the immune response in the current C57BL/6 mouse model. Notably, other investigators recently reported that three human PAP epitopes (114-128, 299-313 and 230-244) were immunologically processed for vaccinations in mice (8). They demonstrated that the PAP (114-128) epitope, which is identical between human and mouse species at the amino acid level, elicits CD4+ and CD8+ T lymphocyte-specific responses in C57BL/6 mice. Furthermore, when administered to mice bearing prostate cancer, the PAP (114-128) peptide prevented and reduced the growth of tumors in the prophylactic and therapeutic settings. These studies showed that the antitumor effects were associated with the infiltration of CD8+ tumor-infiltrating lymphocytes, and proposed that PAP (114-128) is a highly relevant peptide on which to base vaccines for the treatment of prostate cancer. Therefore, it is conceivable that the PAP epitopes, including the peptide (114-128), played essential roles in the anti-PAP vaccination processes in our mouse model after treatment. Additionally, we herein adopted a vaccination strategy using the full-length PAP protein as an immunogen. The use of entire proteins brings about significant advantages, since it can allow the immune cells to present multiple epitopes, including unknown epitopes associated with different MHC class I molecules, in addition to helper epitopes associated with MHC class II molecules (36).

The previously described therapeutic vaccine, sipuleucel-T, is composed of autologous antigen-presenting cells cultured with a fusion protein of PAP-GMCSF, and its administration prolonged the overall survival among patients with metastatic castration-resistant prostate cancer (10). Sipuleucel-T has opened a new era for the treatment of prostate cancer (11), and immunotherapy has become one of the attractive treatment strategies for various cancers. The immune responses to the immunized PAP antigen were augmented in patients who received sipuleucel-T (10), indicating that strategies that can enhance the effects of vaccination are attractive for the next step in immunotherapy. We herein demonstrated the advantages of the in vitro and in vivo combined use of multiple PAP-fused cytokines, including PAP-GMCSF, and therefore propose that the combined use of these fusion proteins could be promising for the enhancement of the immunological effects in prostatic antigen-based vaccination therapy. Moreover, if the super gene expression (SGE) system is applied in the Good Manufacturing Practice (GMP) setting, it could be used for the efficient production and cost-reduction of PAP-fused cytokines for clinical use. Further examinations will be required to apply the current strategy employing the PAP-fused cytokines for ex vivo and in vivo human immunotherapy.

In conclusion, we demonstrated the advantages of the combined use of multiple PAP-fused cytokines, including PAP-GMCSF, under in vitro and in vivo experimental conditions, and propose that this prostatic antigen-based vaccination strategy should be promising for future clinical development. The current findings provide immunological insight for enhancing the therapeutic effects of cytokine-based immunotherapy. It should also be noted that the approach using multiple antigen-fused cytokines is adaptable to other cancer types by changing the prostatic PAP antigen to a different cancer-specific antigen.

Acknowledgements

This study was supported by scientific research grants (KAKENHI: 24390368, 25462478, 25670683 and 26293352) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. We thank Ms. Fusaka Oonari (Okayama University) for her valuable assistance. Okayama University and Momotaro-Gene Inc. are applying for patents on the SGE systems. Okayama University and Dr. M. Watanabe are applying for a patent regarding the cancer antigen-fused cytokines. Dr. M. Watanabe, Dr. Y. Nasu and Dr H. Kumon are the inventors of the patents and own stock in Momotaro-Gene Inc. Dr Kumon is the chief science officer of the company.

References

1. Fong L, Ruegg CL, Brockstedt D, Engleman EG and Laus R: Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 159: 3113-3117, 1997.
2. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL and Engleman EG: Dendritic cell-based xenotransplantation vaccination for prostate cancer immunotherapy. J Immunol 167: 7150-7156, 2001.
3. Roos AK, Pavlenko M, Charo J, Egevad L and Pisa P: Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate 15: 217-223, 2005.
4. Saha A, Chatterjee SK, Mohanty K, Foon KA and Bhattacharya-Chatterjee M: Dendritic cell based vaccines for immunotherapy of cancer. Cancer Ther 1: 299-314, 2003.

5. Matera L: The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer. Cancer Treat Rev 36: 131-141, 2010.

6. Drake CG: Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 10: 580-593, 2010.

7. cytokine released by activated natural killer cells and Kupffer cells: Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous cancer vaccination therapy (Review). Oncol Lett 7: 595-601, 2014.

8. Sait JM, Vadakkelalathau J, Rane SS, McDonald D, Ahmad M, Mathieu M, Pockley AG, Durrant L, Metheringham R, Rees RC and McCarrle SE: Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice. Eur J Immunol 44: 994-1004, 2014.

9. Peshwa MV, Shi J, Ruegg C, Laus R and van Schooten WC: Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 36: 129-138, 1998.

10. Kantoff PW, Higano CS, Shore ND, Alberts DS, Lazenby AJ, gypsum J, Reuter VE, Wei N, Bander NH and Lepage R: Phase II trial of ipilimumab in patients with metastatic castration-resistant prostate cancer. N Engl J Med 363: 411-422, 2010.

11. Di Lorenzo G, Ferro M and Buonerba C: Sipuleucel-T for metastatic castration-resistant prostate cancer. J Clin Oncol 32: 186-199, 2014.

12. Small E, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Shi J, Ruegg C, Laus R and van Schooten WC: Prostate cancer as a model for tumor immunotherapy: the role of BCL-2 and MCL-1. Cytokine 11: 849-855, 1999.

13. Lu X, Park SH, Thompson TC and Lane DP: ras-Induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell 70: 153-161, 1992.

14. Chazen GD, Pereira GM, LeGros G, Gillis S and Shevach EM: Interleukin-7 is a T-cell growth factor. Proc Natl Acad Sci USA 86: 5923-5927, 1989.

15. Barata JT, Silva A, Abecasis M, Carlesso N, Cardoso AA: Molecular and functional evidence for activity of murine IL-17 on human lymphocytes. Exp Hematol 34: 1131-1132, 2006.

16. Kradin RL, Xia W, Pike M, Byers HR and Pinto C: Interleukin-2 promotes the motility of dendritic cells and their accumulation in lung and skin. Pathobiology 64: 180-186, 1996.

17. Bykovskaja SN, Buffo M, Buffo M, hang H, Majors A, Bykovskaja SN and Majors A: Identification and analysis of human erythrocyte REIC/Dkk-3 gene therapy: Development of an autologous cancer vaccination therapy. Mol Med 24: 789-794, 2009.

18. Barata JT, Silva A, Abecasis M, Carlesso N, Caramao A and Cardoso AA: Molecular and functional evidence for activity of murine IL-7 on human lymphocytes. Exp Hematol 34: 1131-1132, 2006.

19. Fujio et al: IMMUNOTHERAPY WITH PAP-FUSED CYTOKINES and limits tumour growth in mice. Eur J Immunol 44: 994-1004, 2014.

20. Sakaguchi M, Watanabe M, Kinoshita R, Kaku H, Ueki H, Futami J, Murata M, Inoue Y, Li SA, Huang P, Putranow ET, Ruma JM, Nasu Y, Kumon H and Huh NH: Radiometric increase in expression of a transgene by insertion of promoters downstream of the gene. Mol Biotechnol 56: 621-630, 2014.

21. Watanabe M, Kashiyakura Y, Huang P, Ochiai K, Futami J, Li SA, Takaoka M, Nasu Y, Sakaguchi M, Huh NH and Kumon H: Immunological aspects of REIC/Dkk-3 in monocyte differentiation and tumor regression. Int J Oncol 34: 657-663, 2009.

22. Kitamura T, Tojo A, Kuswati K, Chiba S, Miyazoko K, Uraha A and Takaku F: Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1. Blood: 373: 357-380, 1989.

23. Charley B, Petit E, Leclerc C and Stefanos S: Production of porcine interleukin-2 and its biological and antigenic relationships with human interleukin-2. Immunol Lett 10: 121-126, 1985.

24. Chazen GD, Pereira GM, LeGros G, Gillis S and Shevach EM: Interleukin-7 is a T-cell growth factor. Proc Natl Acad Sci USA 86: 5923-5927, 1989.

25. Barata JT, Silva A, Abecasis M, Carlesso N, Caramao A and Cardoso AA: Molecular and functional evidence for activity of murine IL-7 on human lymphocytes. Exp Hematol 34: 1131-1132, 2006.

26. Kradin RL, Xia W, Pike M, Byers HR and Pinto C: Interleukin-2 promotes the motility of dendritic cells and their accumulation in lung and skin. Pathobiology 64: 180-186, 1996.

27. Bykovskaja SN, Buffo MJ, Bunker M, Zhang H, Majors A, Herbert M, Lokshin A, Levitt ML, Jaya A, Scalse D, Kosibam D, Evans C, Marks S and Shogan J: Interleukin-2 induces development of dendritic cells from cord blood CD34+ cells. J Leukoc Biol 70: 620-630, 1998.

28. Civalero M, Barni S, nano R and Capelli E: Dendritic cells and interleukin-2: cytokimy and ultrastructural study. Histol Histopathol 15: 1077-1085, 2000.

29. Lynch DH, Namen AE and Miller RE: In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytokine T lymphocytes. Eur J Immunol 21: 2977-2985, 1991.

30. Mackensen A, Lindemann A and Mertelsmann R: Immunostimulatory cytokines in somatic cells and gene therapy of cancer. Cytokine Growth Factor Rev 8: 119-128, 1997.

31. Sakaguchi M, Watanabe M, Kinoshita R, Kaku H, Ueki H, Futami J, Murata M, Inoue Y, Li SA, Huang P, Putranow ET, Ruma JM, Nasu Y, Kumon H and Huh NH: Radiometric increase in expression of a transgene by insertion of promoters downstream of the gene. Mol Biotechnol 56: 621-630, 2014.